Identification, homing and monitoring of therapeutic cells for regenerative medicine:


New tools, technologies and devices establishing regenerative therapies

Establishing regenerative medicine in the clinic is hampered by several limitations that are associated with the complex process of the therapeutic intervention that characterises this innovative medical approach: harvesting of progenitor cells from donor, identify, separate and clone them under GMP condition, transfer them to the recipient and monitor the therapeutic and possible side effects. The IDEA project is dedicated to develop new tools for regenerative medicine. Namely, to develop new photonic methods that allow a contact and marker-free identification and selection of cells prior transplantation, develop and test devices and tracer for homing, capturing and monitoring of such cells in vivo and to guide therapeutic interventions of regenerative medicine by applying new imaging techniques.

Scale-up, regulatory work and exploratory clinical investigations

The IDEA consortium brings together experts from basic and clinical research, medical device industry and drug development. Major effort is paid to translating basic discoveries into clinical practise. First generation magnetic nanoparticles for MPI are available and will be up-scaled under GMP conditions as early as possible for the success of the IDEA project. The magnetic cell select devices will be developed from bench to bedside. Know how of the consortium will allow fast track approval of the medical devices under development. Although it is not the major focus of this proposal, we will test the new products in exploratory clinical studies after initiated, conducted and accomplished an investigational new drug application (IND) for magnetic particles as imaging agent and registration of the magnetic ell select devices (MDR).

Involvement of the European biotechnology industry, especially the SME sector

Progress in the technology driven medical market depends on the dissemination of results to the scientific community which usually is coming from academics AND the penetrating the market with new products which is done by the industry. SMEs play an important role developing high risk products and in doing that they crossing border between the academic field, consumer and industry. The IDEA consortium involves 6 SMEs out of 11 partners. This consortium fulfils basic criteria to increase the speed of development and translation of new products and tools for regenerative medicine.

Impacts on public health

The IDEA project offers the possibility to develop and establish new therapeutic concepts of regenerative medicine that have the potential to overcome the drawbacks and limitations of current cure especially in the ageing population, specifically vascular (myocardial infarct, stroke and peripheral artery disease) and neuronal diseases such as Alzheimer’s and Parkinson’s disease. IDEA thus has the potential to improve the health of European citizens. In addition, the IDEA project will substantially increase the competitiveness boosting the innovative capacity of European health-related industries.